All In Biotech

Drug Trial Radar · NCT06827236

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Apr 23, 2025

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
DualityBio Inc.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).

Conditions

  • Locally Advanced Breast Cancer
  • Unresectable Breast Carcinoma
  • Metastatic Breast Cancer

Interventions

  • BNT323Drug

    Intravenous infusion

  • BNT327Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Occurrence of dose limiting toxicities (DLTs)Time frame: During the DLT evaluation period (Cycle 1), i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days
  2. Occurrence of Treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From the time of initiation of the first dose of IMP to 90 days after the last IMP dose
  3. Occurrence of dose interruption, reduction, and discontinuation due to TEAEsTime frame: From the time of initiation of the first dose of IMP to 90 days after the last IMP dose
  4. Part 2 - Objective response rate (ORR)Time frame: From the time of initiation of the first dose of IMP to last tumor assessment scan, i.e., up to 36 months.

Locations

84 sites in 11 countries. Site status is shown where the registry gives one.

  • Beverly Hills Cancer Center

    Beverly Hills, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Hematology - Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida · Recruiting

  • University Cancer & Blood Center, LLC

    Athens, Georgia · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • University of Illinois Hospital & Health Sciences System

    Chicago, Illinois · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Brigitte Harris Cancer Pavilion BHCP

    Detroit, Michigan · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • Summit Medical Group

    Florham Park, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center Monmouth

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center Bergen

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center Westchester

    Harrison, New York · Recruiting

  • Beth Israel Comprehensive Cancer Center

    New York, New York · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai PRIME

    New York, New York · Recruiting

  • Memorial Sloan Kettering Hospital

    New York, New York · Recruiting

  • Memorial Sloan Kettering Commack

    New York, New York · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center Nassau

    Uniondale, New York · Recruiting

  • Greco Hainsworth Center for Research Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Baylor Scott & White Research Institute -Texas Oncology

    Dallas, Texas · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START), LLC

    San Antonio, Texas · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Australia · Recruiting

  • St Vincent s Hospital Melbourne

    Fitzroy, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • CIUSSS du Saguenay-Lac-Saint-Jean

    Chicoutimi, Canada · Recruiting

  • London Health Sciences Centre (LHSC) - Victoria Hospital

    London, Canada · Recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Canada · Recruiting

  • BC Cancer - Vancouver

    Vancouver, Canada · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.